Drug-Drug Interaction Between Atorvastatin and REZDIFFRA
Yes, there is a clinically significant drug-drug interaction between atorvastatin and REZDIFFRA (resmetirom) that requires dosage adjustment and monitoring.
REZDIFFRA increases atorvastatin exposure, which elevates the risk of statin-related adverse reactions including liver enzyme elevations, myopathy, and rhabdomyolysis 1.
Mechanism and Clinical Impact
REZDIFFRA inhibits OATP1B1 and OATP1B3 transporters, which are critical for hepatic uptake of atorvastatin. This inhibition leads to increased systemic exposure of atorvastatin and its metabolites 1. The FDA label explicitly warns about this interaction and mandates specific management strategies 1.
Required Management Strategy
When combining REZDIFFRA with atorvastatin, you must:
- Reduce the atorvastatin dose - The exact reduction depends on the current atorvastatin dose and clinical context
- Monitor closely for statin-related adverse reactions, specifically:
- Liver function tests (ALT, AST, total bilirubin)
- Muscle symptoms (myalgia, weakness)
- Creatine kinase levels if muscle symptoms develop
- Signs of rhabdomyolysis 1
Critical Monitoring Considerations
This interaction is particularly concerning because REZDIFFRA itself carries a boxed warning for hepatotoxicity, with documented cases of drug-induced autoimmune-like hepatitis showing ALT elevations up to 58× ULN and AST up to 66× ULN 1. When combined with atorvastatin—which also has hepatotoxic potential—the cumulative liver injury risk is amplified.
Monitor liver enzymes more frequently than standard practice when using this combination, and maintain a low threshold for discontinuing either or both medications if transaminase elevations occur.
Common Pitfall to Avoid
Do not assume this interaction is negligible simply because both drugs are commonly used. The FDA specifically included this warning in REZDIFFRA's label based on pharmacokinetic studies demonstrating increased statin exposure 1. Failure to adjust dosing or monitor appropriately could result in serious adverse events including rhabdomyolysis or severe hepatotoxicity.
Note: This interaction is distinct from the well-established safety profile of atorvastatin combined with ezetimibe, which shows no clinically significant pharmacokinetic interaction and is considered safe without dose adjustment 2, 3.